Global private equity company TVM Capital Healthcare has made an equity investment in Human Longevity, a US-based company that specialises in precision medicine and healthy ageing.
The financial details of the investment remain undisclosed.
Go deeper with GlobalData
The deal aims to bolster Human Longevity’s growth in the US and facilitate its expansion into Saudi Arabia and South-East Asia.
It has been channelled through the Saudi Arabia-focused TVM Healthcare Afiyah Fund, which is the country’s largest growth capital fund of its kind.
Human Longevity plans to use the funding to enter the Saudi Arabian market, aligning with the nation’s Vision 2030 plan and Health Sector Transformation Program.
TVM said that Saudi Arabia’s healthcare strategy is shifting from traditional ‘sick care’ to a more holistic ‘health care’ approach, prioritising areas such as oncology, neurology, and cardiovascular disease.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHuman Longevity co-founder and chief scientific adviser Dr Craig Venter said: “Human Longevity is a health firm where the goal is to stay ahead of ageing and illness.
“TVM Capital Healthcare’s investment enables us to strengthen our position globally as the most data-backed longevity practice, as well as establishes our foothold in markets, like Saudi Arabia and South-East Asia, that see the potential of our approach in preventive medicine and the huge impact it will have on changing cost of medicine.”
Based in California, Human Longevity is built on the principle of extending health spans and leveraging genomic science to prevent avoidable diseases.
The company has developed tools for early disease detection and personalised treatment, which aim to encourage predictive and preventative approaches to healthcare.
TVM Capital Healthcare chairman and CEO Dr Helmut Schuehsler said: “With our investment in HLI, we contribute to the transition towards the ‘healthcare of the future’, which is all about precision medicine, personalised care, and disease prevention.”
